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OBJECTIVE: A three-day azithromycin course (500mg/day) was
recently introduced in the US. Our study evaluated patient-
reported outcomes and resource utilization following a three-day
azithromycin course in the treatment of acute exacerbations of
chronic bronchitis (AECB). METHODS: This prospective, mul-
ticenter study evaluated outpatients with AECB who received
either three-day azithromycin (AZM) or 5–14 day courses of
other antibiotics (usual care group; UCG) as directed by the
physician. A total of 128 patients (57 AZM, 71 UCG) completed
two heath-related quality of life instruments, the St. George’s
Respiratory Questionnaire (SGRQ) and Short Form 36 (SF-36),
at baseline, day 14, and end of study (days 24–28), and a diary
for the ﬁrst 14 days after start of antibiotic therapy. RESULTS:
The only difference between treatment groups was a higher per-
centage of diabetics in the UCG compared with the AZM (17%
vs. 2%; P = 0.02). Both groups reported similar improvement in
signs and symptoms, absenteeism, concomitant respiratory med-
ication use, resource utilization, compliance, and treatment sat-
isfaction as reported in the 14-day diary. AZM had signiﬁcant
improvement in all SGRQ measures and in the SF-36 mental and
physical summary components over the course of the study (P <
0.01). The UCG reported signiﬁcant improvement in all SGRQ
measures and in the SF-36 physical component (P < 0.01), but
not in the SF-36 mental component scores (P = 0.10). In total,
78% AZM and 56% UCG had a > four-point improvement on
the SGRQ total score at EOS; however, this difference was not
statistically signiﬁcant in multivariate analysis (P = 0.06). A sig-
niﬁcantly greater activity scale improvement was found for the
AZM group compared with the UCG (P = 0.008). CONCLU-
SIONS: The three-day course of azithromycin 500mg/day had
signiﬁcant impact on patient reported outcomes, as measured by
the SGRQ, SF-36, and patient diary. Further, this regimen pro-
duced a greater improvement on the SGRQ activity scale com-
pared with UCG.
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THE COST-EFFECTIVENESS OF PREVENTING MOTHER-TO-
CHILD TRANSMISSION OF HIV IN CHINA
Zhang H, Zaric GS
University of Western Ontario, London, ON, Canada
OBJECTIVES: Several interventions for reducing mother-to-
child transmission of HIV (MTCT) have been implemented inter-
nationally. In some cities in China, HIV testing is required for
all pregnant women and funding for MTCT prevention is paid
by the government. However, a standard practice has not been
determined. We evaluate the cost-effectiveness of ﬁve interven-
tions for preventing MTCT of HIV in China. METHODS: 
We developed a decision analytic model to compare the costs,
health beneﬁts and cost-effectiveness of the ﬁve alternatives. We
evaluated avoiding breastfeeding only, single-dose nevirapine,
short-course zidovudine, long-course zidovudine, or long-course
HAART. In the base case, we considered national program
implementation in which approximately 15,000,000 women
would receive HIV tests annually. We constructed additional 
scenarios to investigate regional differences in HIV prevalence
cohort size. All costs were expressed in 2003 USD. RESULTS:
HAART is the most cost-effective of the ﬁve interventions if
implemented nation-wide. If HAART was offered to all women
following a positive HIV test result, it would prevent 1,890 new
infections annually and lead to a gain of 39,900 life years (LY).
The total cost is $209,000,000, or $5,200/LY gained. HAART
becomes more cost-effective as the baseline prevalence increases.
In extensive sensitivity analysis, HAART remained the most cost-
effective intervention. If avoiding breastfeeding is already the
status quo, then single-dose nevirapine is the most cost-effective
alternative and is cost saving. CONCLUSIONS: We are not
aware of a cost-effectiveness threshold that is appropriate for
China. However, HAART is the most cost-effective alternative
in a number of different scenarios. In spite of being the most
cost-effective option, the total drug cost of implementing
HAART nationally may necessitate consideration of other 
alternatives.
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VERSUS NELFINAVIR
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The recent SOLO clinical trial demonstrated that the efﬁcacy 
at 48 weeks of HAART regimens containing fosamprenavir/
ritonavir vs. nelﬁnavir in treatment-naïve patients was similar.
However, relative cost comparisons of the two regimens have not
been evaluated in light of the 400% price increase of ritonavir.
OBJECTIVES: A cost comparison analysis was conducted 
of HAART regimens fosamprenavir/ritonavir vs. nelﬁnavir.
METHODS: Clinical efﬁcacy and dosing parameters were
extracted from the SOLO trial and package inserts. Although
recommendations dictate twice daily dosing regimens for pro-
tease inhibitors, the baseline assumption for treatment-naïve
patients was the recommended 1400/200mg once daily dosing
regimen. The efﬁcacy of nelﬁnavir 250mg and 650mg was
assumed to be identical. Sensitivity analysis was conducted on
cost of therapy and cost savings for different scenarios of average
wholesale price (AWP), discounts from the AWP, and number of
tablets per day. Daily, monthly, and 48-week costs of nelﬁnavir
versus ritonavir-boosted fosamprenavir were compared.
RESULTS: Due to the price change in ritonavir, the drug acqui-
sition cost per day of fosamprenavir boosted with ritonavir
increased 73% from $23.48 to $40.71. The nelﬁnavir 625mg
twice daily dosing regimen resulted in monthly cost savings of
$502 and a 48-week cost-reduction of $5545 (41%) compared
to fosamprenavir/ritonavir 1400/200mg once daily regimen. A
discount of approximately 75% on the ritonavir AWP would
make the drug acquisition cost of fosamprenavir boosted with
ritonavir equal to that of nelﬁnavir. CONCLUSION: The price
increase of ritonavir signiﬁcantly affects drug acquisition cost 
for patients taking fosamprenavir and other boosted protease
inhibitors. Without compromising clinical efﬁcacy, nelﬁnavir
provides a cost-saving alternative for treatment-naïve HIV-
infected patients compared to ritonavir-boosted fosamprenavir.
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